PolyPid Ltd (PYPD) heads into a November 28, 2026 PDUFA date with labeling talks underway, a $30 million Azurity partnership already paying off, and cash runway into 2028.
PolyPid's SHIELD II Phase 3 data showed clinically meaningful reductions in surgical site infections. Read why I rate PYPD stock a Buy.
2026-11-01. The following slide deck was published by PolyPid Ltd.
Detailed price information for Polypid Ltd (PYPD-Q) from The Globe and Mail including charting and trades.
WSW, NY, October 9th, 2026, FinanceWireTwo announcements on the same day put a validated European application and full European commercial rights in PolyPid's hands, and may point to value well beyond the U.S. deal
Tipranks Press Release.
PolyPid (NASDAQ:PYPD) is approaching a November 28 PDUFA date for D-PLEX100, its lead product candidate for preventing surgical site infections in patients undergoing colorectal surgery, Chief Executive Officer Dikla Czaczkes Akselbrad said during the Lytham Partners Fall 2026 Investor Conference.
PETACH TIKVA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in the following upcoming investor conferences: 5th Annual ROTH Healthcare Opportunities ConferenceDates: September 29, 2026Location: Metropolitan Club, New York, NYFormat: Panel discuss
This is the newest page. Registered accounts read further back.